Clay Siegall’s Vision for Seattle Genetics

The world of science is filled with discoveries that have yet to be tapped. A majority of companies that deal with scientific research have been making enormous strides to make new discoveries in their area of expertise. One such company is Seattle Genetics. The heart of Seattle Genetics research is human antibodies. Seattle Genetics studies, manipulates, and ultimately comes up with drug that can assist the human antibodies perform their functions better. Clay Siegall founded the research company in the year 1988. The antibodies that Seattle Genetics produces, have the ability that ordinary antibodies do not. The antibodies they manufacture have the ability to deliver a toxic payload to the cancer cells in the body causing them to destroy it from the inside out.

The development of such antibodies could catapult Seattle Genetics to greater heights. With steady growth over the years, the recent research findings could catapult the company to big league category. With a market value of over $10 billion and 900 employees, the company has risen to become one of the largest biotech companies in Washington. It has further grand ambitions of being among the few companies that graduate from a biotech company to a big pharmaceutical company. However, to achieve this dream, they have invested heavily in research and marketing. The additional workforce of 200 employees will help ease the burden of the great tasks they have to accomplish their goal.

One of the achievements of Seattle Genetics is its flagship drug known as Adcetris. The medicine treats Hodgkin lymphoma. Hodgkin lymphoma is a type of cancer that affects the lymph system and can spread if not detected earlier. If the tests that are underway on the drug prove responsive, selling the drug could be a possibility. Clay Siegall, the founder, chairman, and CEO of Seattle Genetics sees a bright future for the company. His ambitions for Seattle Genetics are clear as his desire for the company to move from being a biotech company and focus more on the development of drugs. Clay Siegall has over 20 years’ experience in the study and research of cancer and therapeutic drug development. His in-depth knowledge has helped Seattle Genetics rise to its current position. Apart from being the founder, CEO, and Chairman of Seattle Genetics, he is an author of 67 scientific papers and a holder of 9 patents. He also serves on the three scientific journal editorial boards.